Post-cesarean Pain Control Via Continuous Infusion of Ropivacain et Diclogenac Into the Wound Versus Intathecal Morphine

• Status: Withdrawn
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

The goal is to compare the quality of post-cesarean analgesia, the side effects and the incidence of residual scar pain obtained with intrathecal morphine (reference treatment) or with a continuous intra-wound solution including both ropivacain and diclofenac (experimental treatment).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire de Nīmes
• Treatments: Morphine

Criteria

Inclusion Criteria:

• single, normally progressing pregancy

• term > 36 weeks amenorrhea

• BMI between 20 and 25 kg/m^2 before pregnancy

• height between 55 and 90 kg

• cesarean section by Joel-Cohen or Pfannenstiel techniques

• patient has signed consent

• patient has social security coverage

Exclusion Criteria:

• Multiple pregnancy

• pathological pregnancy: hypertension (>140/90 mmHg found during the pregnancy), pre-eclampsia, gestational diabetes

• term < 36 weeks amenorrhea

• non-pregnancy related maternal pathology (insufficiency)

• obesity (BMI > 25 kg/m^2 before pregnancy)

• height < 155 cm or > 180 cm

• weight < 55 kg or > 90 kg

• patient refuses to sign consent

• surgical technique other than Joel-Cohen or Pfannenstiel

• hepatic insufficiency (prothrombin < 60%)

• contra-indications for rachianesthesia: infection, hemostasis problems (platelets < 80.109/L, prothrombin < 60%, TCA > 40s)

• allergy to local anesthestics

• patient is participating in another study, or has participated in another study within the last 6 months

• patient is under any type of guardianship